Suivre
Abonner Eisai Europe Limited

Eisai Europe Limited

Filtre
  • 20.05.2008 – 11:18

    Inovelon(R) a New Treatment for Lennox-Gastaut Syndrome Reduces Drop Attacks by Over 40%

    London (ots/PRNewswire) - - First EMEA Licensed Treatment Specifically for LGS Offers New Hope for Patients With Epilepsy Eisai Europe Limited, (Headquarters: London, Chairman and CEO Yutaka Tsuchiya) today announced publication of the results of a major study of its new anti-epileptic agent Inovelon (rufinamide) indicated for adjunctive therapy in ...

  • 28.09.2007 – 18:10

    Eisai Announce Application to Appeal NICE Judicial Review Verdict

    London (ots/PRNewswire) - Eisai Limited, the licence holder of Aricept(R) (donepezil hydrochloride) and Pfizer Limited, its co-promotion partner, announced today that Eisai has applied to the Court of Appeal for permission to appeal the recent High Court ruling on the process by which the National Institute for Health and Clinical Excellence (NICE) reached its ...

  • 15.06.2007 – 10:40

    Inovelon(R) A New Treatment for Lennox-Gastaut Syndrome Launched in Europe

    London (ots/PRNewswire) - - First Treatment Licensed Specifically for LGS Offers New Hope for Patients With Epilepsy Eisai Europe Limited, (Headquarters: London, President Yutaka Tsuchiya) today announced the launch in Germany and Scandinavia of its new anti-epileptic agent Inovelon (rufinamide) indicated for adjunctive therapy in Lennox-Gastaut Syndrome ...